

1461
UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new non-provisional
applications under 37 CFR 1.53(b))

 <i>(Only for new non-provisional applications under 37 CFR 1.53(b))</i>	<i>Title of Invention</i>	In Vitro and In Vivo Models for Screening Compounds to Prevent Glucocorticoid-Induced Bone Destruction
	<i>Named Inventor(s)</i>	Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, and Teresita Bellido
	<i>Attorney Docket</i>	06572.105006 CON
	<i>Express Mail Label No.</i>	EV330779150US

15325 U.S. PTO
10/730751

120803

APPLICATION ELEMENTS		ADDRESS TO: Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification, Claims, and Abstract Total Pages 53</p> <p>4. <input checked="" type="checkbox"/> Drawings Total Sheets 5</p> <p>5. Oath or Declaration Total Pages</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input checked="" type="checkbox"/> Copy from prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i></p> <p>(i) <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76.</p> <p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission (<i>if applicable, all necessary</i>)</p> <p>a. <input type="checkbox"/> Computer Readable Form (CRF)</p> <p>b. Specification Sequence Listing on:</p> <p>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</p> <p>ii. <input type="checkbox"/> paper</p> <p>c. <input type="checkbox"/> Statement verifying identity of above copies</p>		ACCOMPANYING APPLICATION PARTS
		<p>9. <input checked="" type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i></p> <p>assignee <input type="checkbox"/> Power of Attorney by</p> <p>11. <input type="checkbox"/> English Translation Document (<i>if applicable</i>)</p> <p>12. <input type="checkbox"/> Information Disclosure Statement (IDS) PTO-1449</p> <p><input type="checkbox"/> Copies of IDS</p> <p>Citations</p> <p>13. <input type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s)</p> <p>16. <input checked="" type="checkbox"/> Assignee: Board of Trustees of the University of Arkansas</p>
<p>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:</p> <p><input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: 09/413,958</p> <p>Prior application information: Examiner: Patrick J. Nolan Group/Art Unit: 1644</p> <p>For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.</p> <p>18. CORRESPONDENCE ADDRESS:</p> <p>Sherry M. Knowles Reg. No. 33,052</p> <p>KING & SPALDING LLP Date: December 8, 2003</p> <p>45th Floor Telephone: 404.572.3541</p> <p>191 Peachtree Street, N.E. Facsimile: 404.572.5145</p> <p>Atlanta, Georgia 30303 Customer No. 20786</p>		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Unassigned
Continuation of 09/413,958 Group Art Unit: 1644
Filed: October 7, 1999 Examiner: Nolan, Patrick J.
Inventor(s) : Stavros Manolagas, *et al.*
Title : In Vitro and In Vivo Models for Screening Compounds to Prevent Glucocorticoid-Induced Bone Destruction
T.C./A.U. : Not yet assigned
Examiner : Not yet assigned
Docket No. : 06572.105006
Customer No.: 20786

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 CFR § 1.53(b)


Sir:

This is a request by Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, and Teresita Bellido for filing a Continuation Application under 37 C.F.R. § 1.53(b) of pending prior application U.S. Serial No. 09/413,958, filed on October 7, 1999, currently pending.

Enclosed is a copy of the prior application U.S.S.N. 09/413,958 as originally filed on October 7, 1999. The application includes fifty-three pages of Specification and five pages Formal Drawings. I hereby verify that the attached papers are a true copy of what is shown in my records to be the above-identified prior application.

Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, and Teresita Bellido have assigned their interest in the application to the Board of Trustees of the University of Arkansas, on October 14, 2003. Copies of the assignments are enclosed. Also enclosed are copies of the executed Declarations for Patent Application and Powers of Attorney and a Preliminary Amendment.

Respectfully submitted,



Sherry M. Knowles
Reg. No. 33,052

Date: December 8, 2003
Express Mail Label EV330779150US

King & Spalding LLP
191 Peachtree Street
Atlanta, Georgia 30303
404-572-3541 (telephone)
404-572-5145 (facsimile)
Attorney Docket No. ANA 1001 CON

CERTIFICATE OF MAILING UNDER 37 CFR § 1.10

FOR UTILITY PATENT APPLICATION FILING

I hereby certify that this Request for filing a Continuation Application, Transmittal of Utility Patent Application, Utility Patent Application, and Fee Transmittal, along with any documents referred to as attached therein are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addresses" services under 37 CFR 1.10, Mailing Label Number EV330779150US addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.



Stephanie D. Adams

Date: December 8, 2003